Few ASX stocks have given investors a more brutal ride than WiseTech Global Ltd (ASX: WTC) this year.

The WiseTech share price has fallen 50% since the start of 2026 and is now trading a long way below its 52-week high of $121.31.

At the time of writing, the stock is down another 1.21% on Friday to $34.21, taking its monthly decline to around 10%.

However, WiseTech has recovered from its low of $28.76 on 23 June. The stock has posted several large daily gains over the past few weeks, although those rallies have often been followed by more selling.

Investors are now weighing comments from management about one of the company’s largest customers, while trying to work out whether the recent low has finally marked the bottom.

Here’s the latest.

WiseTech tries to ease customer concerns

According to The Australian, WiseTech Chief Executive Zubin Appoo is trying to settle concerns about Danish logistics group DSV.

DSV completed its 14.3-billion-euro takeover of DB Schenker in April 2025, creating one of the world’s largest transport and logistics companies.

The issue that’s taking centre stage is that DSV could eventually replace WiseTech’s CargoWise software with Tango, the system acquired through DB Schenker.

However, Appoo said DSV remains an active WiseTech customer and continues to increase its use of CargoWise.

He said:

DSV remains an active WiseTech customer. CargoWise transaction volumes with DSV have grown by around 20 per cent in the last six months.

Take note, the number of DSV users on CargoWise has reportedly increased by around 3% over the same period.

Appoo recently met with DSV Chief Executive Jens Lund and said both companies remain committed to their long-term relationship. DSV’s current contract runs until September 2028.

WiseTech pointed out that large CargoWise installations can take between 5 and 7 years to complete. And that customer attrition has remained below 1% a year over the past 14 years.

Investors are not convinced yet

Despite the reassurance, analysts at Citi still see the potential DSV migration as a risk.

The broker has warned about the issue since February and again highlighted “DSV migration headwinds” this week.

Citi has reportedly reduced its FY28 CargoWise revenue growth forecast to 7%, removing around $80 million from its previous estimate.

This means that the downgrade shows Citi is allowing for some impact, even though DSV hasn’t confirmed it will leave CargoWise.

Has the WiseTech share price bottomed?

There are signs that buyers are stepping in around the low-$30 mark, but the stock is still moving around a lot.

WiseTech shares jumped 14.26% on 24 June, then rose another 7.31% and 5.65% earlier this week. The stock gave back 7.28% on Wednesday.

Keep in mind, the business is still profitable, and CargoWise is widely used across the logistics industry.

And DSV hasn’t confirmed any plans to leave the platform either.

The share price could remain under pressure in the short term, but a stronger-than-expected August result could help shift the mood.

The post Has the WiseTech share price finally hit the bottom after crashing 50%? appeared first on The Motley Fool Australia.

More reading

• 9 ASX 200 shares with reiterated buy calls this week
• Two ASX tech shares hinge on rebuilding trust and growth. Here’s how they can turn around
• How low could WiseTech shares go?
• Why the WiseTech share price is sinking 7% today
• 2 ASX shares tipped to grow 50% or more in the next 12 months

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical Ltd (ASX: 4DX) shares took a breather during Friday’s session, edging 1% higher to $4.10.

The healthcare technology company has pulled back around 12% over the past six months and now trades roughly 46% below the record high it reached in April.

However, the longer-term picture looks very different. This ASX healthcare share is still up an astonishing 1,636% over the past 12 months. Yes, that’s more than sixteen-fold in just one year.

So, after such an extraordinary run, could 4DMedical shares eventually reclaim their all-time high?

Why investors have become so bullish

The biggest catalyst behind the remarkable rise of 4DMedical shares has been growing confidence in its commercial prospects.

The company has developed proprietary respiratory imaging technology that produces four-dimensional lung scans, giving doctors significantly more information than traditional imaging methods. The technology has applications across chronic respiratory diseases, lung cancer, and surgical planning.

Importantly, management has shifted its focus from proving the technology to commercialising it.

US growth and AI investments

Over the past year, 4DMedical has secured several significant contracts and partnerships across the US. Recently, the business signed a major agreement with SimonMed, helping expand its CT:VQ lung imaging technology across the US.

Management believes the deal could lift its addressable market to around US$3 billion with major healthcare providers and government agencies. These agreements have strengthened investor confidence that revenue growth can accelerate as adoption increases.

The company has also continued investing in artificial intelligence capabilities to expand the usefulness of its imaging platform and create additional opportunities within respiratory care.

The path back to record highs

For 4DMedical shares to revisit their April peak, investors will likely need further evidence that commercial momentum is translating into sustainable financial results.

Like many emerging healthcare technology companies, 4DMedical remains focused on scaling its business rather than generating large profits today. That means investors are placing significant value on its future growth potential.

Continued contract wins, increasing scan volumes, expanding recurring revenue, and progress in the US healthcare market could all help support a higher valuation over time.

Heavy investments in research

Despite its enormous gains, 4DMedical remains a higher-risk investment.

Commercialising new medical technology can take longer than expected. Particularly, when healthcare providers require clinical validation and budget approvals before adopting new products.

The company also faces competition from established medical imaging businesses and must continue investing heavily in research, product development, and sales to maintain its competitive advantage.

As a high-growth healthcare stock, 4DMedical shares are also likely to remain volatile. Even positive companies can experience large share price swings as investor sentiment shifts.

The post Up 1,636%, but can 4DMedical shares reclaim their record high? appeared first on The Motley Fool Australia.

More reading

• Which ASX 200 sectors paid the highest dividend yields in FY26?
• This red-hot ASX healthcare share hit a speed bump. What next?
• 13 ASX 200 shares that doubled in value in FY26
• 2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month
• These are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Minerals 260 Ltd (ASX: MI6) this week released the results of a prefeasibility study into its Bullabulling gold project in Western Australia, and it’s fair to say the market was underwhelmed.

While the stock is up more than 440% over the past 12 months, the shares dipped slightly on the publication of the PFS and are now trading at 62 cents.

The analysts at Morgans believe this is cheap and have a bullish share price target on the gold company’s shares, which we’ll get to later.

First, let’s look at what they announced.

Major, long-life gold project in development

The company said in a statement to the ASX that Bullabulling would generate average annual free cash flow of $330 million and would operate for 19 years.

The company would spend $180 million from existing cash reserves to get to a final investment decision, while the mine would cost $560 million to build, plus another $115 million for pre-production operations.

A definitive feasibility study was expected to be completed in the first quarter of calendar year 2027.

Minerals 260 Managing Director Luke McFadyen said regarding the project:

Fifteen months after acquiring the Bullabulling Gold Project, we are presenting outcomes of our PFS and a Maiden Ore Reserve. We always believed Bullabulling could become a significant gold operation, and today’s outcomes confirm the potential for this high-margin, large-scale, long-life Project. Our target of delivering Bullabulling into production by the end of 2028 will establish Minerals 260 as the next mid-tier gold producer on the ASX. With an NPV of $2.3 billion, an IRR of 43% and $510M of average annual EBITDA, Bullabulling is set to deliver significant growth and value for our shareholders.

Shares in this ASX gold company looking cheap

Morgans said, importantly, that the PFS was completed using the previous 4.5 million-ounce gold resource, with an upgraded 6.2 million-ounce resource providing scope for further resource growth.

They added:

The market has reacted negatively to the PFS, which we believe is largely a product of the crystallisation of a sizeable upfront capital requirement rather than any deterioration in project quality. While pre-production capital of ~A$855m is significant, we view it as appropriate for an asset of Bullabulling’s scale, longevity and economic returns, with the project’s strong cash-generative profile expected to support favourable financing outcomes.

Morgans is anticipating first production in mid FY29 with an average output of about 150,000 ounces per year initially.

They added:

We assume a Stage 2 expansion, funded from operating cash flow, is commissioned in 2H FY31, increasing production towards ~200kozpa. Beyond lifting the production profile, the larger-scale operation has the potential to benefit from economies of scale and lower unit operating costs, although we do not currently incorporate these benefits into our base case.

Morgans has a price target of $1.38 on Minerals 260 shares.

The post This oversold ASX gold developer could more than double: Broker appeared first on The Motley Fool Australia.

More reading

• Which ASX 200 sectors paid the highest dividend yields in FY26?
• BHP shares may not double in 12 months but this ASX mining share could
• 5 things to watch on the ASX 200 on Thursday
• 13 ASX 200 shares that doubled in value in FY26
• 5 best ASX 200 mining shares of FY26

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.